The close association of rheumatic fever with hemolytic streptococcal infections has led several investigators to test the applicability of sulfanilamide to the treatment of this disease. The results (1, 2) have indicated that the drug is of no therapeutic value in acute rheumatism. In fact, unlike those diseases which merely fail to respond to sulfanilamide therapy, rheumatic fever is definitely aggravated by the drug. This is not surprising if one considers the unusual sensitivity of p-&"ents with active rheumatism to streptococcal products.
Our observations over the past ten years have shown that rheumatic subjects who escaped hemolytic streptococcal infections also escaped rheumatic fever. It therefore seemed possible that the development of rheumatic attacks might be avoided if streptococcal respiratory infections could be prevented. With this objective in mind, we have conducted studies in the prophylaxis of hemolytic streptococcal infections during the past two years. The data to be reported comprise experiments on guinea pigs and observations on rheumatic subjects.
EXPERIMENTS ON GUINEA PIGS
Streptococcal cervical lymphadenitis or "lumps," an epizootic disease originally described by Smith (3) , was selected as a close parallel in the guinea pig to pharyngitis in the human subject. The prophylactic effect of sulfanilamide was therefore tested on both spontaneous and induced infections of this character. fection to which the healthy pigs were exposed, the infected animals (kindly furnished by Dr. C. V. Seastone of the Rockefeller Institute, Princeton) were alternated daily between the two groups, one of which received sulfanilamide, the other not.
2. Induced infections. In order to avoid the delay involved in the spontaneous transmission of infection through a colony, a matter of many weeks, more severe infections were induced by the introduction of 0.2 cc. of an 18-hour culture of hemolytic streptococcus Group C, Seastone' s strain, Number L7628, into the nares of each pig. The second and third colonies were infected in this way.
3. Sulfanilamide was administered by hypodermoclysis. In the course of 24 hours, each animal received 0.15 gram in the form of a 1 per cent solution of the drug in normal saline. Doses were administered every eight hours. This amount of medication maintained a concentration in heart's blood of 80 to 100 gamma per cc.
4. All animals were examined daily for signs of lymphadenitis.
5. Bacteriological studies were made on pigs which died and on those which were killed. The tissues cultured were lymph glands, heart's blood, liver, spleen, and lung. Cultures were made in broth and on blood agar plates, incubated under both aerobic and anaerobic conditions. 6. Histological studies were made from fixed preparations of the infected foci as well as from lymph glands, lung, liver, spleen, and kidney.
The first colony of 30 animals, exposed to infection by contact with diseased guinea pigs, was divided into two groups: (a) 15 treated with sulfanilamide and (b) 15 controls. The period of exposure was 7 weeks. At the end of this time all 15 of the untreated controls had developed cervical adenitis, and 13 yielded hemolytic streptococcus Group C. At the same time, none of the treated pigs had palpable cervical glands. At autopsy the cervical nodes of 6 animals were slightly larger than normal. Cultures of the entire treated group were negative for hemolytic streptococcus. Although these experiments differed considerably in detail from those of Seastone (4) The second colony of 24 pigs, infected by the introduction of 0.2 cc. of culture in the nares, was divided into two groups, (a) 12 treated with sulfanilamide before and after insufflation of culture, and (b) 12 untreated controls. Within three weeks all controls developed marked enlargement of the cervical glands from each of -which hemolytic streptococcus Group C was cultured. The treated animals appeared to be normal. They were killed at this time and on autopsy the cervical glands were found to be slightly enlarged in all pigs. However, hemolytic streptococcus Group C was isolated from only 4 of the 12 pigs.
The occurrence of slight cervical enlargement and the absence of organisms on culture or smear in 8 animals suggested that organisms might b;e present in the glands and be controlled by the bacteriostatic action of sulfanilamide. The following experiment investigated this possibility. A third colony of 24 pigs were all treated with sulfanilamide before and after infection by the nasal route. After 14 days chemotherapy was discontinued. Half of the animals were killed (Group 1). Their cervical glands were removed under sterile precautions, ground, and injected into the abdomen of 12 normal pigs (Group 3). The remaining 12 pigs (Group 2) were kept without further medication.
One month later Groups 2 and 3 were sacrificed. The animals in Group 3 were all found to be normal and all cultures were sterile. Hemolytic streptococcus was recovered from 4 out of 12 pigs in Group 2.
In summary, sulfanilamide appeared to give complete protection to a colony of guinea pigs against spontaneous lymphadenitis with Group C hemolytic streptococcus. Sulfanilamide seemed to protect about two-thirds of the animals which received a large dose of the same organisms intranasally, and modified the disease in the remaining third.
CLINICAL STUDIES
Study I Limited observations (5) had suggested that the incidence of septic complications following streptococcal infections might be diminished-by sulfanilamide therapy during the infections. We therefore investigated the effect of sulfanilamide, administered during pharyngitis, on the incidence of rheumatic recrudescences.
The patients were selected from a group of rheumatic subjects who have been under our observation for a number of years. Each hemolytic streptococcal throat infection that was seen by us within 24 hours of the onset of symptoms was treated for 5 to 14 days with sulfanilamide. Patients who contracted similar infections but did not report their symptoms until after 24 hours were used as controls. Careful observations were made on a group of 40 children and young adults. The results are summarized in Table I . From Table I it is seen that 13 treated cases 2 and 11 untreated cases developed rheumatic manifestations. The latter were possibly a little more severe. Sulfanilamide therapy begun after the onset of pharyngitis appeared to have no effect as a prophylactic agent in preventing rheumatic recrudescences. These findings are in accord with the observations of Massell (1) .
The efficacy of sulfanilamide in preventing guinea pigs from contracting spontaneous Group C infections suggested that it might also be of use in preventing the occurrence of Group A respiratory infections in human subjects. To investigate this possibility three additional clinical studies were carried out.
Study 2
Procedure. The patients were 29 rheumatic girls between the ages of 6 and 14 who were convalescing at the Pelham Home. The majority were quiescent, a few had evidences of smouldering rheumatism. Except for monthly visits from relatives, their contacts were limited to the personnel of Pelham Home. 3 No new patients were admitted to the Home during the experiment, which ran from January 9 to June 17, 1937.
Each patient was given by mouth approximately 2 grams of sulfanilamide daily, divided into three doses distributed as evenly as possible throughout the 24 hours. Medication was maintained for the whole period of observation. Previous experience (5) had shown that drug symptoms occurred less frequently in children than in adults and did not develop later than two weeks from the start of therapy.
Two throat cultures were obtained from each patient once a week. In addition, cultures were taken of all patients at the onset of any respiratory infection.
Blood sedimentation rates were determined twice a month. Urinalysis and blood counts were done several times during the course of the experiment.
A careful clinical history was taken daily and a physical examination made once a week.
Results. No patients developed any drug manifestations. A few showed slight anorexia and failed to gaini weight. There was no evidence of blood destruction or renal irritation.
Hemolytic streptococcus was present in the throat flora of 6 patients at the time medication was started. Two of these were carriers, and continued to harbor the organism throughout most of the period. The other 4 became negative within a month after the drug was started. Hemolytic streptococcus appeared briefly in the 8 The Pelham Home is a convalescent home caring for 30 girls with rheumatic heart disease. The personnel comprises a teacher, 3 nurses, and 3 domestics. throat flora of one other patient at about the middle of the period of observation.
The clinical results may be described as follows: (a) Four patients who already had hemolytic streptococcus in the throat flora at the start showed brief mild rheumatic recrudescences within a few days after starting sulfanilamide. (b) Six patients experienced vague symptoms. It was impossible to know whether these were related to rheumatic activity. (c) Nineteen patients were entirely symptom-free throughout the period.
The blood sedimentation rates remained normal in all but 5 individuals. Four of these rises were transient, occurring in the patients who developed rheumatic symptoms on starting the drug. The fifth occurred during a severe attack of bronchitis.
In summary, during the course of the study there were no drug symptoms, no frank streptococcal infections, and no attacks of acute rheumatism. Sulfanilamide did not prevent the occurrence of a number of " common colds," one pneumococcus ear infection, and one severe bronchitis of unknown etiology.
Study 3
The findings in Study 2 again suggested that sulfanilamide might be of prophylactic value in streptococcal respiratory infections. The third study was planned to obtain critical information on a group of rheumatic children known to be exposed to hemolytic streptococcal infection. In the foregoing study which was performed in a closed colony, there was no indication that the patients had contact with streptococcal infection other than their association with two known carriers of this organism. In the course of Study 3, 4 new patients were admitted to The Pelham Home at different times. One of these was recovering from pharyngitis, another from tonsillectomy, and the other two had acute rheumatism.
Procedure. The general procedure was the same as in Study 2, with certain exceptions, as follows:
(a) Six patients from whom sulfanilamide was withheld for various reasons served as untreated controls.
(b) The dosage level was raised gradually over the first 2 weeks to approximately 2 grams per patients per day.
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(c) The concentration of sulfanilamide in the blood was determined every two weeks. Blood samples were collected at various times after medication to include diurnal fluctuations.
Results. As in Study 2, no patient developed drug manifestations, but failure to gain weight was noted in a few instances.
The blood sulfanilamide concentration remained fairly constant after the maintenance dosage was established. The average blood concentration for all patients varied between 29 and 55 gammas per cc. with a general average of 39 gammas for the whole group. The individual data are presented in Table II . these the organism appeared for 48 hours in moderately large numbers, coincident with respiratory symptoms (Vol). In the other, 3 or 4 colonies were isolated from each of 3 widely spaced cultures. They were not accompanied by symptoms of any sort.
Of the 6 unmedicated patients, 4 had hemolytic streptococcus in the throat flora on one or more occasions. These data are summarized in Table  III .
The clinical results showed that 25 out of the 26 medicated patients remained free of rheumatic activity. One patient developed changes which could be interpreted as active rheumatism. This girl (Vol) had a respiratory infection and cervical adenitis and maintained a high blood sedimentation rate over a period of several months in the absence of fever, tachycardia, rise in antistreptolysin titer, and rheumatic symptoms. It seems wisest to classify this case as rheumatic activity, although it was not possible to make a definite diagnosis.
The absence of rheumatic activity in patients receiving sulfanilamide is well illustrated by the sedimentation rates listed in Table IV. In summary, these observations showed that quiescent rheumatic subjects can be maintained for many months at a high blood sulfanilamide level without demonstrable ill effects. These patients were visited by their families, were exposed to 2 patients with streptococcal infections who were introduced into The Pelham Home, and lived in close proximity with a carrier of hemolytic streptococcus and with 6 non-medicated patients who had positive cultures or rheumatic activity or both at some time during the experiment. Only one of the 26 medicated patients con'tracted an infection with hemolytic streptococcus in the throat flora. Twenty-five highly susceptible rheumatic children were main'tained in good health throughout the winter and spring months.
Study 4 Although the patients in Study 3 were livin'g in close contact with one another in a small institution, nevertheless their general environment with respect to nutrition, housing, and rest facilities was much better than that in which the average rheumatic child in New York City lives. Ava.... 0000 00000 0000 00000 0000 0000 0000 0000 00 0 0 0 Cap.... 0000 00000 0000 00000 0000 0000 0000 0000 00 0 0 0 Cis .... 0000 00000 000 0 0 0000 0 000 0 0 00 000 0 0 000 00 0 0 0 Edw... 0000 00000 0000 0 0000 0 000 0 0 00 0 0 00 0000 0 0
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Kov. . This group consisted of 30 highly susceptible rheumatic subjects from 8 to 14 years of age.4
All were known to have contracted frequent streptococcal respiratory infections during previ- 4 Most of them gave a strong familial rheumatic history. All had rheumatic heart disease with at least mitral involvement. Each had had one or more frank attacks of rheumatic fever requiring hospital care. A few had had recrudescences annually during the 3 or 4 years previous to this study. Results. Twenty of the 30 patients who started the study continued medication throughout the entire course. They will be referred to as Group A. The other ten (Group B) took the medication for only a part of the whole period, and served as controls.
In Group A none of the patients developed drug manifestations. In Group B, the appearance of drug symptoms in 3 patients made it necessary for them to discontinue sulfanilamide during the first week of the experiment. The concentration of sulfanilamide in the blood was maintained at an average level of from 31 to 62 gammas per cc., with a general average of 41 gammas for the whole group, as shown in Table V .
Five members of Group B stopped medication during the early fall because of drug symptoms. Three of these became infected with hemolytic streptococcus during the winter.
The other five remained under medication for 4 to 7 months, during which time none showed a positive throat culture. Of 4 who remained in New York City after stopping the drug, 3 contracted hemolytic streptococcal infection within 2 months. Altogether, 6 patients in Group B became infected after stopping sulfanilamide, and 3 of these infections were followed by rheumatic recrudescences. The occurrence of hemolytic streptococcus in the throat cultures of these 30 children are presented in Table VI . It is not possible to estimate how frequently these children were exposed to infection in their normal home and school environment. However, it was determined that epidemics of streptococcal infection occurred in the families of 3 patients in Group A and did not affect the children taking sulfanilamide.
Only one patient (Cro) had hemolytic streptococcus in the throat flora at the onset of the experiment. One patient (Cur) who was admitted to the group December 1, with cervical adenitis, and who was started on medication at once, yielded a positive culture of hemolytic streptococcus 3 days later. We could not be sure whether infection with this organism preceded or followed the administration of the drug. It was possible in 3 other patients to obtain a few colonies of hemolytic streptococcus from the throat flora on one or two occasions. None of these organisms had the mucoid or matt colony appearance of virulent strains, nor did they give rise to respiratory infections. Their cultures died in the course of 2 mon'ths' storage in blood broth before they could be classified in Lancefield's groups. In summary, this group of 20 patients appeared to escape streptococcal respiratory infection although a number of them had "common colds " and one developed measles. They also escaped clinical evidence of rheumatic fever. Their freedom from rheumatic activity can best be visualized from the record of their sedimen'tation rates, given in Table VII Sulfanilamide used prophylactically prevented spontaneous infections and either prevented or modified the development of induced hemolytic streptococcal cervical adenitis in the guinea pig.
Sulfanilamide administered to rheumatic subjects after the onset of streptococcal throat infections did not prevent rheumatic recrudescences.
The possible prophylactic use of sulfanilamide was tested in 80 rheumatic children. Seventynine escaped hemolytic streptococcal infection and signs of rheumatic activity.
